Published online Sep 16, 2026. doi: 10.5314/wjd.117337
Revised: December 19, 2025
Accepted: January 19, 2026
Published online: September 16, 2026
Processing time: 284 Days and 17.3 Hours
Pityriasis lichenoides (PL) is considered a clinicopathologic continuum ranging from acute PL et varioliformis acuta to chronic PL chronica (PLC). Although his
To characterize the clinicopathologic spectrum of PL in a real-world adult cohort and to evaluate the adjunctive contribution of dermoscopy to disease assessment.
We retrospectively reviewed 19 consecutive patients with biopsy-confirmed PL. Demographic data, clinical characteristics, histopathologic findings, treatment modalities, and outcomes were extracted from medical records. Dermoscopic features were analyzed in a subset of patients using a polarized handheld der
PLC was the most frequent presentation, while a substantial proportion of pa
This case series highlights the dynamic and overlapping nature of PL. Dermo
Core Tip: Pityriasis lichenoides (PL) consists of overlapping clinicopathologic patterns rather than strictly separated PL et varioliformis acuta and PL chronica categories. This 19-patient series highlights the frequency of transitional forms and demonstrates how dermoscopy mirrors underlying histopathologic activity, offering a simple, noninvasive tool to distinguish acute from chronic lesions in routine practice. Recognizing these dynamic features may improve diagnostic accuracy and reduce unnecessary biopsies.
- Citation: Kaya G. Clinicopathological spectrum of pityriasis lichenoides: A case series of 19 patients. World J Dermatol 2026; 12(1): 117337
- URL: https://www.wjgnet.com/2218-6190/full/v12/i1/117337.htm
- DOI: https://dx.doi.org/10.5314/wjd.117337
Pityriasis lichenoides (PL) is increasingly regarded as a clinicopathologic continuum linking acute PL et varioliformis acuta (PLEVA) and chronic PL chronica (PLC), rather than as distinct entities[1]. Although its precise etiology remains unclear, histologic and immunologic evidence supports a T-cell-mediated inflammatory response, potentially triggered by infections or medications, with occasional reports of clonal T-cell expansions raising concerns about lymphoproliferative potential[2].
Despite well-established histopathologic criteria, real-world clinicopathologic correlation in adult patients remains limited, particularly in cases with overlapping or transitional features between PLEVA and PLC. Moreover, dermoscopic descriptions of PL are scarce and largely restricted to small case series, leaving the practical role of dermoscopy in routine disease assessment insufficiently defined[3,4].
In this context, we present a single-centre retrospective case series of 19 biopsy-confirmed PL patients, aiming to characterize the clinicopathologic spectrum of the disease and to illustrate the adjunctive contribution of dermoscopy in reflecting disease activity and supporting clinicopathologic correlation in clinical practice.
This retrospective observational case series included 19 consecutive patients diagnosed with PL at a single secondary dermatology centre between January 2022 and June 2025. Patients were identified through a retrospective review of electronic medical records and institutional pathology databases. All included cases had histopathologically confirmed PL based on punch biopsy and clinicopathologic correlation. No preselection was performed based on disease severity or treatment history.
Patients with clinicopathologic features suggestive of alternative diagnoses, including cutaneous T-cell lymphoma, were excluded following comprehensive clinical assessment and histopathologic evaluation by experienced dermatopathologists. Immunohistochemical staining and T-cell receptor gene rearrangement studies were not routinely performed, which is acknowledged as a limitation of the retrospective design.
Cases were classified as PLEVA, PLC, or indeterminate PL spectrum based on combined clinical and histopathologic criteria. PLEVA was characterized by acute clinical presentation with necrotic keratinocytes, prominent erythrocyte ex
Clinical photographs and dermoscopic images, when available, were reviewed by a dermatologist. Dermoscopic exa
Demographic characteristics, clinical features, treatment modalities, and follow-up outcomes were extracted from ele
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. As per institutional policy, formal ethics committee approval was not required for retrospective studies using fully anonymized clinical data. Written informed consent for the publication of anonymized clinical information, dermoscopic images, and histopathologic figures was obtained from all patients or their legal guardians.
Nineteen patients (14 women and 5 men; mean age 58 years, range 25-84) were identified during the study period. The lower limbs and trunk were the most frequently involved anatomical sites. Histopathologic examination commonly de
Based on combined clinicopathologic assessment, 11 patients were classified as PLC, 2 as PLEVA, and 6 as inde
Most patients were treated with topical corticosteroids, with or without oral antihistamines. Narrowband ultraviolet B phototherapy was administered in four patients, and low-dose methotrexate was used in six patients, occasionally in combination with other treatment modalities. Representative clinical and dermoscopic findings are illustrated in Figure 1.
The median disease duration at presentation was 3 years (range, 1 month-12 years), with longer disease courses ob
| Classification | n (%) | Mean age (years) | Female (%) | Disease duration, median (range) |
| PLC | 11 (58) | 56 | 82 | 3 years (1-12 years) |
| PLEVA | 2 (11) | 79 | 50 | 0.5 year (1 month-1 year) |
| PL spectrum (indeterminate) | 6 (32) | 53 | 67 | 3.5 years (6 months-9 years) |
| Total | 19 | 57.6 (25-84) | 74 | 3 years (1 month-12 years) |
This single-centre cohort underscores the clinicopathologic continuum of PL, encompassing both PLEVA and PLC[5]. Approximately one-third of patients in our series exhibited overlapping or indeterminate features, supporting previous observations that PL represents a dynamic spectrum rather than discrete clinicopathologic entities[6].
Dermoscopy provided a useful, non-invasive reflection of histopathologic activity. In acute and overlapping lesions, central reddish-brown crusts surrounded by a white collarette and a peripheral vascular ring composed of dotted, linear-irregular, or glomerular vessels corresponded to the polymorphous “targetoid” pattern described in recent reports[7,8]. These vascular features likely reflect papillary dermal capillary dilation and microhemorrhage associated with active inflammation. In contrast, chronic PLC-like lesions demonstrated brown-crusted plugs, yellow-brown structureless areas, and sparse dotted vessels, consistent with residual or post-inflammatory changes.
Recognition of these dermoscopic patterns may support disease staging and assist clinicopathologic correlation in routine practice, while histopathologic confirmation remains essential. From a therapeutic perspective, the use of topical corticosteroids, narrowband UVB phototherapy, and low-dose methotrexate in our cohort is consistent with existing lite
Overall, integrating dermoscopy with clinical and histopathologic assessment may enhance diagnostic confidence and facilitate individualized, stepwise management strategies for this chronic relapsing disorder.
This study highlights the overlapping and transitional features of PL across its acute and chronic forms, supporting the concept of a clinicopathologic disease continuum. Dermoscopy may serve as a practical, non-invasive adjunct to clini
Limitations of this study include its retrospective design, the relatively small sample size, and the absence of der
The author would like to thank the staff of the Dermatology Clinic at Gaziantep Nizip State Hospital and the dermatopathologists at Gaziantep 25 Aralık State Hospital for their contributions to both the diagnostic evaluation and clinical management of the cases.
| 1. | Lupu J, Chosidow O, Wolkenstein P, Bergqvist C, Ortonne N, Ingen-Housz-Oro S. Pityriasis lichenoides: a clinical and pathological case series of 49 patients with an emphasis on follow-up. Clin Exp Dermatol. 2021;46:1561-1566. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 2. | Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007;8:29-36. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 78] [Cited by in RCA: 68] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
| 3. | Peñuelas Leal R, Labrandero Hoyos C, Grau Echevarría A, Blaya Imbernon D, Finello M, Magdaleno Tapial J, Alegre De Miguel V. Dermoscopy as a diagnostic aid in pityriasis lichenoides et varioliformis acuta. Clin Exp Dermatol. 2024;49:149-154. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 4. | Alba-Rojas E, Guerra-Garza AS, Ocampo-Candiani J. Diagnostic Dermoscopy in Pityriasis Lichenoides Chronica and Pityriasis Lichenoides et Varioliformis Acuta: A Case Series. Dermatol Pract Concept. 2025;15:5078. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 5. | Bellinato F, Maurelli M, Gisondi P, Girolomoni G. A systematic review of treatments for pityriasis lichenoides. J Eur Acad Dermatol Venereol. 2019;33:2039-2049. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 10] [Cited by in RCA: 32] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
| 6. | Jung F, Sibbald C, Bohdanowicz M, Ingram JR, Piguet V. Systematic review of the efficacies and adverse effects of treatments for pityriasis lichenoides. Br J Dermatol. 2020;183:1026-1032. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5] [Cited by in RCA: 11] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
| 7. | Arias-Rodriguez C, Hoyos-Gaviria JG, Muñoz-Monsalve AM, Hernandez-Martinez A. Dermoscopy of pityriasis lichenoides et varioliformis acuta (PLEVA). An Bras Dermatol. 2024;99:120-123. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 8. | Lacarrubba F, Micali G. Dermoscopy of pityriasis lichenoides et varioliformis acuta. Arch Dermatol. 2010;146:1322. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 6] [Article Influence: 0.4] [Reference Citation Analysis (0)] |
| 9. | Hrin ML, Bowers NL, Jorizzo JL, Feldman SR, Huang WW. Methotrexate for pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease) and pityriasis lichenoides chronica: A retrospective case series of 33 patients with an emphasis on outcomes. J Am Acad Dermatol. 2022;86:433-437. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 3] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
| 10. | Agaoglu E, Erdogan HK, Acer E, Saracoglu ZN, Bilgin M. Narrowband ultraviolet B phototherapy for pityriasis lichenoides: A real-life experience. Photodermatol Photoimmunol Photomed. 2023;39:520-526. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |